鼓膜置管治疗单侧梅尼埃病:前瞻性、假手术对照、双盲、随机临床试验方案
本方案描述一项前瞻性、假手术对照、双盲、随机临床试验,旨在评估鼓膜置管对符合Bàràny学会分类委员会标准的明确或 probable 单侧梅尼埃病的疗效。主要结局为持续超过20分钟的自发性眩晕发作次数及治疗失败时间。预计纳入104例受试者(每组52例),按意向性治疗原则分析,试验于2021年启动,预计2025年结束。
要点
- 鼓膜置管是简单、相对安全、微创的操作,既往开放标签试验显示有希望的结果。
- 本试验为前瞻性、假手术对照、双盲、随机临床试验,针对明确或 probable 单侧梅尼埃病。
- 主要结局为持续超过20分钟的自发性眩晕发作次数及治疗失败时间。
核心结论
- 本试验旨在评估鼓膜置管与假手术治疗明确或 probable 单侧梅尼埃病的效果。
研究设计与样本
- 前瞻性、假手术对照、双盲、随机临床试验,预计纳入104例受试者,每组52例,按意向性治疗原则分析。
主要发现
- 主要结局为持续超过20分钟的自发性眩晕发作次数及治疗失败时间。
- 次要结局包括听力、耳闷胀感、头晕及严重不良事件。
关键数值与推荐
- 受试者需符合Bàràny学会分类委员会制定的明确或 probable 单侧梅尼埃病标准。
- 样本量估计共104例,每组52例。
- 主要分析采用意向性治疗原则。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Menière's disease is an idiopathic disorder characterized by recurrent episodes of vertigo lasting more than 20 min, unilateral sensorineural hearing loss, and tinnitus. If vertigo attacks occur frequently, the patient is usually severely incapacitated. Currently, there is no consensus on the treatment of Menière's disease. The evidence regarding most treatment options is sparse due to a lack of randomized trials together with an often-spontaneous relief over time and a considerable placebo effect. Insertion of a transmyringeal tube is a simple and relatively safe, minimally invasive procedure and previous open-label trials have shown promising results. STUDY DESIGN: This is a prospective, sham-controlled, double-blinded, randomized, clinical trial. AIM: This trial aims to assess the effects of inserting a ventilation tube into the tympanic membrane compared with sham treatment for definite or probable unilateral Menière's disease according to the criteria formulated by the Classification Committee of the Bàràny Society. OUTCOMES: The primary outcome will be the number of spontaneous vertigo attacks lasting more than 20 min and time to treatment failure. In addition to the primary outcome, we will assess various secondary outcomes related to hearing, ear fullness, dizziness, and serious adverse events. SAMPLE SIZE: An estimated 104 participants in total or 52 participants in each group will be necessary. The primary analysis will be according to the intention-to-treat principle. The trial will be initiated in 2021 and is expected to end in 2025. TRIAL STATUS: ClinicalTrials.gov : NCT04835688 . Registered on April 8, 2021. PROTOCOL VERSION: 1.8, 26-09-2022. Date of first enrollment: October 1st, 2021. End of study: anticipated January 2025.
引用
- Larsen CG, Karlberg M, Guldfred F, et al. Transmyringeal ventilation tube insertion for unilateral Menière's disease: a protocol for a prospective, sham-controlled, double-blinded, randomized, clinical trial. Trials. 2022. PMID: 36253829. doi:10.1186/s13063-022-06777-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。